TNDM vs. ICUI, IART, NARI, PRCT, ATEC, LMAT, AXNX, IRTC, NVCR, and ATRC
Should you be buying Tandem Diabetes Care stock or one of its competitors? The main competitors of Tandem Diabetes Care include ICU Medical (ICUI), Integra LifeSciences (IART), Inari Medical (NARI), PROCEPT BioRobotics (PRCT), Alphatec (ATEC), LeMaitre Vascular (LMAT), Axonics (AXNX), iRhythm Technologies (IRTC), NovoCure (NVCR), and AtriCure (ATRC). These companies are all part of the "surgical & medical instruments" industry.
Tandem Diabetes Care (NASDAQ:TNDM) and ICU Medical (NASDAQ:ICUI) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, institutional ownership, community ranking, risk, valuation, dividends, earnings and analyst recommendations.
96.1% of ICU Medical shares are owned by institutional investors. 2.2% of Tandem Diabetes Care shares are owned by company insiders. Comparatively, 6.7% of ICU Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
ICU Medical has higher revenue and earnings than Tandem Diabetes Care. ICU Medical is trading at a lower price-to-earnings ratio than Tandem Diabetes Care, indicating that it is currently the more affordable of the two stocks.
Tandem Diabetes Care currently has a consensus target price of $44.50, indicating a potential downside of 0.49%. ICU Medical has a consensus target price of $123.00, indicating a potential upside of 23.01%. Given ICU Medical's stronger consensus rating and higher probable upside, analysts plainly believe ICU Medical is more favorable than Tandem Diabetes Care.
ICU Medical has a net margin of -1.31% compared to Tandem Diabetes Care's net margin of -18.37%. ICU Medical's return on equity of 6.35% beat Tandem Diabetes Care's return on equity.
Tandem Diabetes Care received 184 more outperform votes than ICU Medical when rated by MarketBeat users. However, 64.48% of users gave ICU Medical an outperform vote while only 60.97% of users gave Tandem Diabetes Care an outperform vote.
In the previous week, Tandem Diabetes Care had 21 more articles in the media than ICU Medical. MarketBeat recorded 26 mentions for Tandem Diabetes Care and 5 mentions for ICU Medical. Tandem Diabetes Care's average media sentiment score of 1.13 beat ICU Medical's score of 0.52 indicating that Tandem Diabetes Care is being referred to more favorably in the media.
Tandem Diabetes Care has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500. Comparatively, ICU Medical has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500.
Summary
ICU Medical beats Tandem Diabetes Care on 11 of the 18 factors compared between the two stocks.
Get Tandem Diabetes Care News Delivered to You Automatically
Sign up to receive the latest news and ratings for TNDM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TNDM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tandem Diabetes Care Competitors List
Related Companies and Tools
